Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 547 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ July 31, 2019 Cómo compartir los resultados de las pruebas genéticas con la familia March 22, 2022 FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction... November 17, 2023 FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma November 13, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) Epigenetic Changes Pinpointed as the Cause of Some GISTs Why it’s difficult to estimate the number of extra cancer deaths... Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors
